
    
      This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and
      efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or
      Alopecia Totalis (AT) in adult subjects. Subjects will be required to have a clinical
      diagnosis of stable AA, AU, or AT. A total of approximately 80 subjects will be randomized.
    
  